Chemicrea

Chemicrea is a Japan-based biotechnology company focused on the discovery of innovative small molecule drugs using its proprietary chemical library and synthesis platform. Spun out from the University of Tokyo, the company specializes in targeting challenging biological pathways, particularly protein-protein interactions (PPIs), which are often considered undruggable. Chemicrea's platform utilizes a unique collection of structurally complex and diverse compounds to identify high-affinity leads for various therapeutic areas, including oncology and immunology. The company operates primarily through strategic research collaborations with major pharmaceutical partners to co-develop and commercialize its drug candidates. By combining advanced organic chemistry with biological screening, Chemicrea aims to provide novel therapeutic solutions for unmet medical needs.